TITLE

Risk assessment for bleeding during warfarin therapy

AUTHOR(S)
Kuritzky, Louis
PUB. DATE
December 2010
SOURCE
Internal Medicine Alert;12/15/2010 Supplement, p183
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the role of the HAS-BLED stratification tool in evaluating one-year risk of bleeding in patients with atrial fibrillation (AF) who were undergoing warfarin therapy.
ACCESSION #
57803289

 

Related Articles

  • Warfarin as a stroke prevention agent in patients with atrial fibrillation.  // Australian Journal of Pharmacy;Aug2012, Vol. 93 Issue 1107, p94 

    The article presents information on a study related to the use of Warfarin as a stroke prevention agent in patients with atrial fibrillation.

  • Bleeding risk with rivaroxaban similar to warfarin in AF.  // Reactions Weekly;1/25/2014, Issue 1485, p3 

    The article discusses the ROCKET Atrial Fibrillation (AF) double-blind trial in which patients with AF who are at risk for stroke were assigned to rivaroxaban or dose -adjusted warfarin treatment which found the similarity of bleeding risk in both drugs.

  • Stroke patients PROSPER with warfarin.  // PharmacoEconomics & Outcomes News;Aug2015, Vol. 734 Issue 1, p23 

    The article reports on the findings of the Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study that show the effectiveness of the anticoagulant warfarin among ischemic stroke patients with atrial fibrillation.

  • Warfarin safe for AF in CKD patients.  // Pulse;Apr2014, p19 

    The article focuses on a Swedish study which revealed that anticoagulant drug warfarin could lessen the risk of thrombotic cases in patients with chronic kidney disease (CKD) and atrial fibrillation (AF).

  • GP REGISTRAR: Atrial fibrillation - part two. Newson, Louise // GP: General Practitioner;11/24/2003, p56 

    Although there is plenty of evidence to support anticoagulation in patients with atrial fibrillation to reduce the risk of stroke, many patients are still not receiving warfarin. Anticoagulation is under-used because it is not known whether trial efficacy translates in practice. The patients in...

  • Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. Connolly, Smart J; Kalra, Lalit // BMJ: British Medical Journal (International Edition);05/06/2000, Vol. 320 Issue 7244, p1236 

    Objective:To determine whether trial efficacy of prophylaxis with warfarin for patients with atrial fibrillation at high risk of stroke translates into effectiveness in clinical practice.

  • Risk assessment for bleeding during warfarin therapy.  // Primary Care Reports;Jan2011 Clinical Briefs in Primary, Vol. 16 Issue 1, p1 

    The article reports on the benefits of warfarin anticoagulant drug given to atrial fibrillation patients, and provides CHADS scores to help clinicians assess bleeding risks on patients with conditions including hypertension, abnormal renal/hepatic function, and stroke.

  • Warfarin initiation increased stroke risk within 30 days of use.  // Cardiology Today;Mar2014, Vol. 17 Issue 3, p22 

    The article discusses research being done on the effect of warfarin on patients with atrial fibrillation, referencing a study by L. Azoulay published in a 2013 issue of "European Heart Journal."

  • Commentary. Garcia, David; Hylek, Elaine // Evidence Based Medicine;Apr2007, Vol. 12 Issue 2, p57 

    The author comments on a study which investigates whether the contemporary bleeding risk model can predict major bleeding in patients with atrial fibrillation (AT) who are receiving warfarin therapy. It is asserted that the model accurately predicts the patient's risk of major bleeding, enabling...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics